Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

This study is testing a combination of futibatinib (a targeted drug blocking FGFR, a protein that drives some bladder cancers) and durvalumab (an immunotherapy) given before bladder removal surgery in people with muscle-invasive bladder cancer who cannot receive standard cisplatin-based chemotherapy. **You may be eligible if...** - You are 18 or older and weigh more than 30 kg - You have confirmed urothelial carcinoma of the bladder at Stage T2–T4a (muscle-invasive, no spread to lymph nodes or distant sites) - Your tumor has a specific protein change (FGFR overexpression) detected by a lab test - You cannot receive cisplatin-based chemotherapy due to kidney function, hearing loss, nerve damage, or heart function - You are otherwise fit for and planning to have your bladder surgically removed - You are in reasonably good health (ECOG score 0, 1, or 2) **You may NOT be eligible if...** - You do not have FGFR overexpression - You have cancer that has spread beyond the bladder and nearby lymph nodes - You received prior anti-PD-1/PD-L1 therapy less than 3 months ago - You are pregnant or breastfeeding - You have significant heart, eye, or bone problems related to FGFR inhibitor side effects Talk to your doctor to see if this trial is right for you.